Literature DB >> 10946316

Association of deficient type II protein kinase A activity with aberrant nuclear translocation of the RII beta subunit in systemic lupus erythematosus T lymphocytes.

N Mishra1, I U Khan, G C Tsokos, G M Kammer.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder of indeterminate etiology characterized by abnormal T cell signal transduction and altered T cell effector functions. We have previously observed a profound deficiency of total protein kinase A (PKA) phosphotransferase activity in SLE T cells. Here we examined whether reduced total PKA activity in SLE T cells is in part the result of deficient type II PKA (PKA-II) isozyme activity. The mean PKA-II activity in SLE T cells was 61% of normal control T cells. The prevalence of deficient PKA-II activity in 35 SLE subjects was 37%. Deficient isozyme activity was persistent over time and was unrelated to SLE disease activity. Reduced PKA-II activity was associated with spontaneous dissociation of the cytosolic RIIbeta2C2 holoenzyme and translocation of the regulatory (RIIbeta) subunit from the cytosol to the nucleus. Confocal immunofluorescence microscopy revealed that the RIIbeta subunit was present in approximately 60% of SLE T cell nuclei compared with only 2-3% of normal and disease controls. Quantification of nuclear RIIbeta subunit protein content by immunoprecipitation and immunoblotting demonstrated a 54% increase over normal T cell nuclei. Moreover, the RIIbeta subunit was retained in SLE T cell nuclei, failed to relocate to the cytosol, and was associated with a persistent deficiency of PKA-II activity. In conclusion, we describe a novel mechanism of deficient PKA-II isozyme activity due to aberrant nuclear translocation of the RIIbeta subunit and its retention in the nucleus in SLE T cells. Deficient PKA-II activity may contribute to impaired signaling in SLE T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946316     DOI: 10.4049/jimmunol.165.5.2830

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  CREMα suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells.

Authors:  Debjani Ghosh; Katalin Kis-Toth; Yuang-Taung Juang; George C Tsokos
Journal:  Arthritis Rheum       Date:  2012-03

2.  Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells.

Authors:  N Mishra; D R Brown; I M Olorenshaw; G M Kammer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

3.  Altered regulation of IL-2 production in systemic lupus erythematosus: an evolving paradigm.

Authors:  Gary M Kammer
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 4.  T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.

Authors:  Vaishali R Moulton; George C Tsokos
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

5.  Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

Authors:  Nilamadhab Mishra; Christopher M Reilly; Doris R Brown; Phil Ruiz; Gary S Gilkeson
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 6.  Abnormalities of T cell signaling in systemic lupus erythematosus.

Authors:  Vaishali R Moulton; George C Tsokos
Journal:  Arthritis Res Ther       Date:  2011-03-17       Impact factor: 5.156

7.  Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus.

Authors:  Peter Gergely; Brian Niland; Nick Gonchoroff; Rudolf Pullmann; Paul E Phillips; Andras Perl
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.